HRP20210184T1 - Peptidni dendrimeri koji sadrže fibrinogen-vezujuće peptide - Google Patents
Peptidni dendrimeri koji sadrže fibrinogen-vezujuće peptide Download PDFInfo
- Publication number
- HRP20210184T1 HRP20210184T1 HRP20210184TT HRP20210184T HRP20210184T1 HR P20210184 T1 HRP20210184 T1 HR P20210184T1 HR P20210184T T HRP20210184T T HR P20210184TT HR P20210184 T HRP20210184 T HR P20210184T HR P20210184 T1 HRP20210184 T1 HR P20210184T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- fbp
- peptide
- fibrinogen
- linker
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 24
- 239000000412 dendrimer Substances 0.000 title claims 17
- 229920000736 dendritic polymer Polymers 0.000 title claims 17
- 102000008946 Fibrinogen Human genes 0.000 title claims 9
- 108010049003 Fibrinogen Proteins 0.000 title claims 9
- 229940012952 fibrinogen Drugs 0.000 title claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 22
- VWJLJHZPMZGDDV-HOCDWTQPSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCC(O)=O)C1=CN=CN1 VWJLJHZPMZGDDV-HOCDWTQPSA-N 0.000 claims 6
- 125000000524 functional group Chemical group 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000009697 arginine Nutrition 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 235000004554 glutamine Nutrition 0.000 claims 2
- 239000000017 hydrogel Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000863 peptide conjugate Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Peptidni dendrimer koji sadrži razgranatu jezgru i mnoštvo peptida koji vežu fibrinogen, odvojeno kovalentno vezani za razgranatu jezgru, pri čemu razgranata jezgra sadrži:
od dva do deset multifunkcionalnih aminokiselinskih ostataka, pri čemu svaki fibrinogen koji veže peptid je odvojeno kovalentno vezan za višenamjenski aminokiselinski ostatak razgranate jezgre;
mnoštvo multifunkcionalnih aminokiselinskih ostataka, pri čemu su jedan ili više peptida koji vežu fibrinogen odvojeno kovalentno vezani za svaki od najmanje dva susjedna multifunkcionalna aminokiselinska ostatka razgranate jezgre;
mnoštvo višenamjenskih aminokiselinskih ostataka, pri čemu su dva ili više peptida koji vežu fibrinogen odvojeno kovalentno vezani za barem jedan od višenamjenskih aminokiselinskih ostataka razgranate jezgre;
mnoštvo višenamjenskih aminokiselinskih ostataka, pri čemu su dva ili više višenamjenskih aminokiselinskih ostataka kovalentno povezani kroz bočni lanac susjednih višenamjenskih aminokiselinskih ostataka; ili
jedan višenamjenski aminokiselinski ostatak, a peptid koji veže fibrinogen odvojeno je kovalentno vezan za svaku funkcionalnu skupinu višenamjenskog aminokiselinskog ostatka; pri čemu višenamjenski aminokiselinski ostaci sadrže tri- ili tetra-funkcionalne aminokiselinske ostatke, ili su tri- ili tetra-funkcionalni aminokiselinski ostaci, ili je pojedinačni višenamjenski aminokiselinski ostatak tri- ili tetrafunkcionalni aminokiselinski ostatak;
pri čemu tri-funkcionalni aminokiselinski ostaci obuhvaćaju središnji atom ugljika koji nosi amino skupinu, karboksilnu skupinu i bočni lanac koji nosi daljnju funkcionalnu skupinu, a tetra-funkcionalni aminokiselinski ostaci obuhvaćaju središnji atom ugljika koji sadrži amino skupinu, karboksilna skupina i bočni lanac koji nosi daljnje dvije funkcionalne skupine.
2. Peptidni dendrimer prema zahtjevu 1, naznačen time da razgranata jezgra sadrži mnoštvo uzastopnih multifunkcionalnih aminokiselinskih ostataka i po mogućnosti do deset višenamjenskih aminokiselinskih ostataka.
3. Peptidni dendrimer prema bilo kojem prethodnom zahtjevu, sljedeće opće formule (I):
[image]
gdje je:
FBP peptid koji veže fibrinogen;
-(linker)- je neobavezni linker, po mogućnosti nepeptidni linker;
X je tri-funkcionalni aminokiselinski ostatak, po mogućnosti lizin, ornitin, arginin, asparaginska kiselina, glutaminska kiselina, asparagin, glutamin ili cisteinski ostatak;
Y je –FBP, ili -NH2;
Z je -(linker)-FBP kada je Y -FBP, ili -[-Xn-(linker)-FBP]a-(linker)-FBP kada je Y -NH2, ili - [-Xn-(linker)-FBP]a-(linker)-FBP kada je Y-FBP;
gdje je:
Xn tri-funkcionalni aminokiselinski ostatak, po mogućnosti lizin, ornitin, arginin, asparaginska kiselina, glutaminska kiselina, asparagin, glutamin ili cisteinski ostatak; a
a je 1-10, po mogućnosti 1-3.
4. Peptidni dendrimer prema bilo kojem od prethodnih zahtjeva, slijedeće opće formule (II):
[image]
gdje:
FBP je peptid koji veže fibrinogen;
-(linker)- je neobavezni linker, koji poželjno sadrži -NH(CH2)5CO-;
Y je -FBP ili -NH2;
Z je:
-R-(Iinker)-FBP, kada je Y -FBP, ili
[image]
kada je Y -NH2; ili
[image]
kada je Y -NH2; ili
[image]
kada je Y -NH2; ili
[image]
kada je Y –FBP i a je 1-10, poželjno 1-3 gdje R je -(CH2)4NH-, -(CH2)3NH, ili -(CH2)3NHCNHNH.
5. Peptidni dendrimer u skladu s bilo kojim od prethodnih patentnih zahtjeva, sljedeće opće formule (III):
[image]
gdje je:
FBP je peptid koji veže fibrinogen;
-(linker)- je neobavezni linker, koji poželjno sadrži -NH(CH2)5CO-;
Y je –FBP, ili -NH2;
Z je:
-(CH2)4NH-(linker)-FBP, kada je Y –FBP; ili
[image]
kada je Y -NH2; ili
[image]
kada je Y -NH2; ili
[image]
kada je Y -NH2; ili
[image]
kada je Y –FBP i a je 1-10, poželjno 1-3.
6. Peptidni dendrimer u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je svaki peptid koji veže fibrinogen vezan na razgranatu jezgru ne-peptidnim linkerom.
7. Peptidni dendrimer u skladu s patentnim zahtjevom 6, naznačen time što linker sadrži ravan lanac linkera, po mogućnosti ravnolančanu alkilnu skupinu, i još poželjnije -NH(CH2)nCO-, gdje n je 1-10.
8. Pripravak koji sadrži peptidni dendrimer prema bilo kojem od zahtjeva 1 do 7, i peptidni konjugat koji sadrži dva ili više peptida koji vežu fibrinogen.
9. Farmaceutski pripravak, koji sadrži peptidni dendrimer prema bilo kojem od zahtjeva 1 do 7, ili pripravak prema zahtjevu 8, i farmaceutski prihvatljiv nosač, pomoćnu tvar, ili razrjeđivač.
10. Postupak sterilizacije peptidnog dendrimera prema bilo kojem od zahtjeva 1 do 7, ili pripravak u skladu s patentnim zahtjevom 8, koji obuhvaća izlaganje peptidnog dendrimera ili pripravka gama zračenju, po mogućnosti do 30 kGy.
11. Postupak polimerizacije fibrinogena, naznačen time što obuhvaća kontakt fibrinogena s peptidnim dendrimerom u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili sa pripravkom prema zahtjevu 8.
12. Komplet za tvorbu hidrogela, naznačen time što sadrži peptidni dendrimer prema bilo kojem od zahtjeva 1 do 7, ili pripravak prema zahtjevu 8, i odvojeno, fibrinogen.
13. Hidrogel koji sadrži kopolimer peptidnog dendrimera prema bilo kojem od zahtjeva 1 do 7 ili smjese prema zahtjevu 8, i fibrinogen.
14. Peptidni dendrimer prema bilo kojem od zahtjeva 1 do 7, ili pripravak prema zahtjevu 8, naznačen time da se upotrebljava kao lijek.
15. Peptidni dendrimer prema bilo kojem od zahtjeva 1 do 7, ili pripravak prema zahtjevu 8, naznačen time da se koristi u liječenju krvarenja ili za liječenje rane.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400292.7A GB201400292D0 (en) | 2014-01-08 | 2014-01-08 | Peptide dendrimers and agents |
| EP15701237.8A EP3092011B1 (en) | 2014-01-08 | 2015-01-08 | Peptide dendrimers comprising fibrinogen-binding peptides |
| PCT/GB2015/050024 WO2015104544A1 (en) | 2014-01-08 | 2015-01-08 | Peptide dendrimers comprising fibrinogen-binding peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210184T1 true HRP20210184T1 (hr) | 2021-04-30 |
Family
ID=50191056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210184TT HRP20210184T1 (hr) | 2014-01-08 | 2021-02-02 | Peptidni dendrimeri koji sadrže fibrinogen-vezujuće peptide |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10994047B2 (hr) |
| EP (1) | EP3092011B1 (hr) |
| JP (1) | JP6717747B2 (hr) |
| KR (1) | KR102410065B1 (hr) |
| CN (1) | CN105916524B (hr) |
| AU (1) | AU2015205438B2 (hr) |
| BR (1) | BR112016015701A2 (hr) |
| CA (1) | CA2935888A1 (hr) |
| ES (1) | ES2848031T3 (hr) |
| GB (1) | GB201400292D0 (hr) |
| HR (1) | HRP20210184T1 (hr) |
| IL (1) | IL246611A0 (hr) |
| MX (1) | MX370174B (hr) |
| PH (1) | PH12016501308A1 (hr) |
| RU (1) | RU2719562C2 (hr) |
| SG (1) | SG11201605581UA (hr) |
| WO (1) | WO2015104544A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508024D0 (en) * | 2015-05-11 | 2015-06-24 | Haemostatix Ltd | Haemostatic compositions |
| WO2018065789A1 (en) | 2016-10-06 | 2018-04-12 | Matoke Holdings Limited | Antimicrobial compositions |
| US20200030347A1 (en) | 2016-10-06 | 2020-01-30 | Matoke Holdings Limited | Antimicrobial compositions |
| CN107625968B (zh) * | 2017-09-20 | 2020-09-29 | 四川大学 | 一种肿瘤特异性组织-细胞双渗透纳米粒、制备方法及其应用 |
| CN111356479A (zh) * | 2018-01-04 | 2020-06-30 | 安瑞特研究有限公司 | 含有白桦脂醇的桦树皮提取物及其制剂 |
| CA3054228A1 (en) * | 2018-09-06 | 2020-03-06 | Intercontinental Exchange Holdings, Inc. | Multi-signature verification network |
| CN110448719B (zh) * | 2019-06-28 | 2020-05-22 | 浙江大学 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
| CA3172138A1 (en) * | 2020-03-31 | 2021-10-07 | Marika G. Rioult | Sterilization of self-assembling peptides by irradiation |
| US11666682B2 (en) * | 2020-08-31 | 2023-06-06 | Ethicon, Inc. | Method of stopping CSF leaks and apparatus therefor |
| CN112206307B (zh) * | 2020-09-15 | 2023-12-05 | 广州领晟医疗科技有限公司 | 一种可注射的温敏型水凝胶及其制备方法与应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0796115A1 (en) | 1994-12-07 | 1997-09-24 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| GB9524630D0 (en) * | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| CN1222918A (zh) * | 1996-06-21 | 1999-07-14 | 曾尼卡有限公司 | 细胞粘连抑制剂 |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| FR2813080B1 (fr) * | 2000-08-17 | 2002-11-29 | Stago Diagnostica | Peptides anti-heparine |
| US6506365B1 (en) * | 2000-09-25 | 2003-01-14 | Baxter Aktiengesellschaft | Fibrin/fibrinogen binding conjugate |
| WO2004045494A2 (en) | 2002-11-20 | 2004-06-03 | Bar-Ilan University | Biological glue based on thrombin-conjugated nanoparticles |
| CN1835723B (zh) | 2003-06-16 | 2011-06-22 | 洛马林达大学医学中心 | 可展开的多功能止血剂 |
| CA2574773A1 (en) | 2004-07-22 | 2006-02-02 | Allan D. Pronovost | Compositions and methods for treating excessive bleeding |
| GB0516091D0 (en) * | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
| GB0623607D0 (en) * | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
| US20100021527A1 (en) | 2008-07-25 | 2010-01-28 | Chunlin Yang | Collagen-related peptides and uses thereof and hemostatic foam substrates |
| US20130310853A1 (en) | 2009-01-09 | 2013-11-21 | Abbott Cardiovascular Systems Inc. | Method and apparatus for percutaneous treatment of a blood vessel |
| US8513380B2 (en) * | 2009-07-09 | 2013-08-20 | Georgia Tech Research Corporation | Peptides for binding fibrinogen and fibrin |
| GB201101740D0 (en) * | 2011-02-01 | 2011-03-16 | Haemostatix Ltd | Therapeutic agents with improved fibrinogen binding |
| EP2582051A1 (en) | 2011-10-13 | 2013-04-17 | ST-Ericsson SA | Multi-level sigma-delta ADC with reduced quantization levels |
| GB201201751D0 (en) * | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
-
2014
- 2014-01-08 GB GBGB1400292.7A patent/GB201400292D0/en not_active Ceased
-
2015
- 2015-01-08 JP JP2016544565A patent/JP6717747B2/ja active Active
- 2015-01-08 MX MX2016008876A patent/MX370174B/es active IP Right Grant
- 2015-01-08 CA CA2935888A patent/CA2935888A1/en active Pending
- 2015-01-08 ES ES15701237T patent/ES2848031T3/es active Active
- 2015-01-08 AU AU2015205438A patent/AU2015205438B2/en active Active
- 2015-01-08 KR KR1020167019889A patent/KR102410065B1/ko active IP Right Grant
- 2015-01-08 WO PCT/GB2015/050024 patent/WO2015104544A1/en active Application Filing
- 2015-01-08 CN CN201580004811.1A patent/CN105916524B/zh active Active
- 2015-01-08 EP EP15701237.8A patent/EP3092011B1/en active Active
- 2015-01-08 US US15/110,630 patent/US10994047B2/en active Active
- 2015-01-08 BR BR112016015701A patent/BR112016015701A2/pt not_active Application Discontinuation
- 2015-01-08 RU RU2016130448A patent/RU2719562C2/ru active
- 2015-01-08 SG SG11201605581UA patent/SG11201605581UA/en unknown
-
2016
- 2016-06-30 PH PH12016501308A patent/PH12016501308A1/en unknown
- 2016-07-05 IL IL246611A patent/IL246611A0/en unknown
-
2021
- 2021-02-02 HR HRP20210184TT patent/HRP20210184T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2848031T3 (es) | 2021-08-05 |
| KR20160105820A (ko) | 2016-09-07 |
| PH12016501308A1 (en) | 2016-08-15 |
| IL246611A0 (en) | 2016-08-31 |
| US10994047B2 (en) | 2021-05-04 |
| JP2017505298A (ja) | 2017-02-16 |
| RU2016130448A (ru) | 2018-02-16 |
| GB201400292D0 (en) | 2014-02-26 |
| CN105916524A (zh) | 2016-08-31 |
| AU2015205438B2 (en) | 2018-11-08 |
| US20160324977A1 (en) | 2016-11-10 |
| MX2016008876A (es) | 2016-12-02 |
| BR112016015701A2 (pt) | 2017-10-03 |
| AU2015205438A1 (en) | 2016-08-11 |
| CN105916524B (zh) | 2021-07-20 |
| RU2719562C2 (ru) | 2020-04-21 |
| RU2016130448A3 (hr) | 2018-06-25 |
| EP3092011B1 (en) | 2020-11-18 |
| JP6717747B2 (ja) | 2020-07-01 |
| SG11201605581UA (en) | 2016-08-30 |
| WO2015104544A1 (en) | 2015-07-16 |
| KR102410065B1 (ko) | 2022-06-16 |
| CA2935888A1 (en) | 2015-07-16 |
| MX370174B (es) | 2019-12-04 |
| EP3092011A1 (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210184T1 (hr) | Peptidni dendrimeri koji sadrže fibrinogen-vezujuće peptide | |
| HRP20190387T1 (hr) | Pripravci koji preskaču ekson za dmd | |
| HRP20191852T1 (hr) | Polipeptidi | |
| HRP20210342T1 (hr) | Pripravci glikopeptida | |
| CY1122226T1 (el) | Προφαρμακα που περiλαμβανουν συζευγμα εξενδινης αρθρωτη | |
| HRP20171175T1 (hr) | Novi triciklički spojevi | |
| AR082862A1 (es) | Forma de dosificacion resistente a alteracion que comprende un polimero anionico | |
| JP2010521485A5 (hr) | ||
| EP4345100A3 (en) | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
| JP2015513533A5 (hr) | ||
| JP2007530441A5 (hr) | ||
| DE602005008996D1 (de) | Radiofluorierte peptide | |
| EA201390600A1 (ru) | Терапевтические наночастицы с сополимерами с большим молекулярным весом | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| CO6491083A2 (es) | Profarmacos que comprenden un conugado de insulina-conector | |
| JP2013514329A5 (hr) | ||
| RU2014124333A (ru) | Блок-сополимер, имеющий введенную в него группу фенилбороновой кислоты, и его применение | |
| JP2014532628A5 (hr) | ||
| HRP20171180T4 (hr) | Pegilirana l-asparaginaza | |
| HRP20150523T1 (hr) | Kombinacija za lijeäśenje mukozitisa izazvanog zraäśenjem ili kemoterapijom | |
| JP2017530192A5 (hr) | ||
| CL2012002808A1 (es) | Composición que comprende un polímero derivado de al menos dos monómeros: acrilico-x y una alquilamina, en donde el peso molecular del polimero es de entre 500 a 200.000 y, ademas, el polimero es modificado para contener un grupo funcional capaz de depurar una o mas composiciones que contienen uno o mas metales. | |
| CY1119012T1 (el) | Ασφαλτικη συνθεση σε μορφη κοκκων και μεθοδος παρασκευης της | |
| FR2994975B1 (fr) | Copolyamide, composition comprenant un tel copolyamide et leurs utilisations | |
| EA201590790A1 (ru) | СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b |